Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DINGELL TRADE HEARINGS WILL REVIEW DRUG PATENT PROTECTION

Executive Summary

DINGELL TRADE HEARINGS WILL REVIEW DRUG PATENT PROTECTION afforded U.S. pharmaceutical companies by foreign trading partners. The hearings are set for March 1-2 by the House Energy Commerce/Oversight Subcommittee, chaired by Rep. Dingell (D-Mich.). The Pharmaceutical Manufacturers Association (PMA) is scheduled to appear during the first day of the hearings as part of a panel on export problems. The panel will address barriers to product entry into foreign countries as well as intellectual property rights violations. The Motion Picture Association was also invited to testify. A second panel testifying March 1 will address unfair import practices such as counterfeiting. PMA President Mossinghoff is expected to include in his testimony a list of trading partners who have violated the intellectual property rights of U.S. drug companies. The association said Brazil and India head up the list. On the second day of the hearings, recently appointed U.S. Trade Representative (USTR) Carla Hills has been invited to outline her plans for the implementation of the Trade Act, including the recently revised Section 301. Through revisions in the Trade Act enacted by Congress last year, 301 has been beefed up to provide additional protection against particularly egregious offenses by trading partners. Under what is now known as "super 301," the USTR is directed to develop by this spring a comprehensive list of countries that are not trading fairly with the U.S. The USTR would then begin negotiations with those countries, and, if the alleged trading inequities are not resolved within a specified period of time, impose appropriate sanctions. PMA's list of countries has already been forwarded to the Office of the USTR. The hearings are designed to lay the groundwork for the subcommittee to monitor the implementation of the Trade Act. Similar hearings are scheduled for March 1 and April 19 in the Senate Finance Committee, chaired by Sen. Bentsen (D-Texas). PMA is planning to submit the same testimony in writing to Bentsen's committee. Hills will testify March 1. In a press release announcing the hearings, Bentsen said his committee "will vigorously oversee implementation of the Omnibus Trade and Competitiveness Act of 1988." He added that "the new Trade Act sets some specific requirements on the new Administration with regard to trade policy, and we have reason to be concerned these requirements may not be fully implemented on time." As examples, the senator cited recent news reports that the White House has taken too long to write rules enforcing a ban on goods from Toshiba of Japan, and that Japan plans to lobby for less than full enforcement of Section 301.(ITEM 200)#050928M001J59307# #970804M001XFCWP5# (ITEM 201)(COPYRIGHT) 1989 F-D-C Reports, Inc., The Pink Sheet, February 20, 1989

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel